Rank: 81
2016 Rank96
R&D Spend:$28,973,000
Fiscal year ending:12-31-16
Click here to see all 100

Cynosure is a developer and manufacturer of a broad array of light-based aesthetic and medical treatment systems. Our products are used to provide a diverse range of treatment applications such as hair removal, skin revitalization and scar reduction, as well as the treatment of vascular lesions.

Cynosure Receives FDA Clearance to Market New PicoSure Energy Delivery System for Tattoos and Pigmented Lesions. CynoSure Brings the Speed of Light to Non-Invasive Body Contouring...Introducing SculpSure. Cynosure Receives Health Canada Authorization to Market MonaLisa Touch for Genitourinary Syndrome of Menopause. Cynosure Receives Regulatory Clearance in China to Market PicoSure Picosecond Laser for Tattoo Removal. Cynosure Receives CE Mark Approval for SculpSure. Cynosure to Host Investor Event to Introduce SculpSure, the World's First Hyperthermic Aesthetic Laser Treatment for Non-Invasive Fat Reduction. Cynosure Receives Expanded FDA 510(k) Clearance To Market SculpSure for Non-Invasive Lipolysis of the Abdomen. Cynosure Receives FDA 510(k) Clearance for SculpSure, the World's First Hyperthermic Laser Treatment for Non-Invasive Fat Reduction. Cynosure Announces FDA Clearance of New 532 nm Laser Delivery System for PicoSure.

Big 100 Mini Logo Key Personnel: Michael Davin, chairman, president & CEO; Timothy Baker, COO & CFO; Douglas Delaney, EVP, sales;

5 Carlisle Road
Westford, MA